Physician profile
Daniela Garza
NPI 1689123218
$7,007.85
in general payments reported to CMS, 2019-2025
31 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $2,367 · 2023: $1,892 · 2024: $1,462 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,752.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.03 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $877.80 | 2021-2024 | Airsupra |
| Aurinia Pharma U.S., INC. | $795.53 | 2022-2023 | Lupkynis |
| Amgen INC. | $517.50 | 2022-2023 | Tavneos |
| Lilly USA, LLC | $512.87 | 2022-2025 | Mounjaro, Taltz, Zepbound |
| Glaxosmithkline, LLC. | $373.38 | 2022-2025 | Benlysta |
| Dexcom, INC. | $364.70 | 2021-2025 | Dexcom G6 Transmitter |
| Nevro Corp. | $323.88 | 2024 | Senza |
| Inspire Medical Systems, INC. | $306.19 | 2023-2025 | Inspire |
| Genentech USA, INC. | $178.98 | 2021-2022 | |
| Janssen Biotech, INC. | $172.31 | 2022-2023 | Simponi Aria, Tremfya |
| Intuity Medical INC | $148.90 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ultragenyx Pharmaceutical INC. | $125.00 | 2022 | |
| Horizon Therapeutics Plc | $120.83 | 2021 | |
| Abbott Laboratories | $119.69 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $115.92 | 2024 | Wegovy |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.90 | 2024 | Cabtreo |
| Esperion Therapeutics, INC. | $109.47 | 2021 | |
| Organogenesis INC. | $108.61 | 2025 | Affinity |
| Medtronic, INC. | $105.88 | 2021 | |
| Gilead Sciences, INC. | $100.63 | 2024 | Epclusa |
| Phathom Pharmaceuticals, INC. | $93.22 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.07 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.80 | 2023 | |
| Novartis Pharmaceuticals Corporation | $31.06 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $26.35 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $19.73 | 2023 | Uzedy |
| Phadia US INC. | $19.61 | 2022 | |
| Radius Health, INC. | $18.15 | 2022 | |
| Pfizer INC. | $17.36 | 2024 | |
| Mallinckrodt Hospital Products INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.